Compare Stocks: LIAN, SCNX, TVRD, and BFRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.30 +3.2%	$1.08	$0.55 ▼ $1.40	$16.13M	0.78	388,241 shs	972,630 shs
LIAN LianBio	$0.04	$0.09	$0.27 ▼ $4.99	$4.40M	0.23	1.04 million shs	N/A
SCNX Scienture	$0.47 +0.2%	$0.38	$0.24 ▼ $2.60	$18.89M	3.26	1.97 million shs	29.55 million shs
TVRD Tvardi Therapeutics	$1.90 +7.3%	$2.49	$1.50 ▼ $43.65	$16.60M	0.39	513,662 shs	345,662 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	+0.80%	+0.80%	+18.87%	+57.50%	+32.63%
LIAN LianBio	+5.71%	-10.15%	-63.20%	-63.53%	-20.66%
SCNX Scienture	+3.33%	+24.77%	+19.54%	+15.38%	-79.05%
TVRD Tvardi Therapeutics	0.00%	-4.32%	-42.90%	-55.75%	-92.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.30 +3.2%	$1.08	$0.55 ▼ $1.40	$16.13M	0.78	388,241 shs	972,630 shs
LIAN LianBio	$0.04	$0.09	$0.27 ▼ $4.99	$4.40M	0.23	1.04 million shs	N/A
SCNX Scienture	$0.47 +0.2%	$0.38	$0.24 ▼ $2.60	$18.89M	3.26	1.97 million shs	29.55 million shs
TVRD Tvardi Therapeutics	$1.90 +7.3%	$2.49	$1.50 ▼ $43.65	$16.60M	0.39	513,662 shs	345,662 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	+0.80%	+0.80%	+18.87%	+57.50%	+32.63%
LIAN LianBio	+5.71%	-10.15%	-63.20%	-63.53%	-20.66%
SCNX Scienture	+3.33%	+24.77%	+19.54%	+15.38%	-79.05%
TVRD Tvardi Therapeutics	0.00%	-4.32%	-42.90%	-55.75%	-92.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
LIAN LianBio	0.00	N/A	N/A	N/A
SCNX Scienture	2.00	Hold	$1.50	221.96% Upside
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	847.37% Upside

Current Analyst Ratings Breakdown

Latest LIAN, SCNX, TVRD, and BFRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/15/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
7/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/29/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$41.71M	0.40	N/A	N/A	$0.90 per share	1.44
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
SCNX Scienture	$477.68K	39.63	N/A	N/A	$1.73 per share	0.27
TVRD Tvardi Therapeutics	$7.14M	2.50	N/A	N/A	$2.23 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.97	N/A	21.67	N/A	-13.78%	-155.98%	-31.69%	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-51.84%	-42.22%	N/A
TVRD Tvardi Therapeutics	-$18.21M	-$3.10	N/A	N/A	N/A	N/A	-64.17%	-43.90%	N/A

Latest LIAN, SCNX, TVRD, and BFRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million
5/15/2026	Q1 2026	SCNX Scienture	-$0.23	-$0.08	+$0.15	-$0.08	$0.40 million	$0.06 million
5/14/2026	Q1 2026	BFRI Biofrontera	-$0.1150	-$0.41	-$0.2950	-$0.41	$10.25 million	$10.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.20	1.09
LIAN LianBio	N/A	10.06	10.06
SCNX Scienture	N/A	1.70	1.63
TVRD Tvardi Therapeutics	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
LIAN LianBio	74.85%
SCNX Scienture	5.68%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
LIAN LianBio	7.59%
SCNX Scienture	21.39%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	70	12.80 million	11.77 million	No Data
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
SCNX Scienture	N/A	40.63 million	31.94 million	N/A
TVRD Tvardi Therapeutics	80	9.38 million	8.69 million	N/A

LIAN, SCNX, TVRD, and BFRI Headlines

Recent News About These Companies

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12 at 8:00 AM | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

Tvardi Therapeutics Inc.

July 7, 2026 | cnn.com

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | finance.yahoo.com

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | globenewswire.com

TVRD Share News Today

June 29, 2026 | uk.investing.com

Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting

June 27, 2026 | theglobeandmail.com

Tvardi Therapeutics, Inc. Common Stock

June 27, 2026 | fxempire.comF

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

June 25, 2026 | theglobeandmail.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures

June 11, 2026 | tipranks.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026 | globenewswire.com

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

May 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LIAN, SCNX, TVRD, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

$1.30 +0.04 (+3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 +0.02 (+1.54%)

As of 07:45 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

LianBio NASDAQ:LIAN

$0.04 0.00 (0.00%)

As of 08/13/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Scienture NASDAQ:SCNX

$0.47 +0.00 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$0.46 0.00 (-1.05%)

As of 07:59 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

Tvardi Therapeutics NASDAQ:TVRD

$1.90 +0.13 (+7.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.89 -0.01 (-0.47%)

As of 07:37 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIAN, SCNX, TVRD, and BFRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIAN, SCNX, TVRD, and BFRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIAN, SCNX, TVRD, and BFRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LIAN, SCNX, TVRD, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

LianBio NASDAQ:LIAN

Scienture NASDAQ:SCNX

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIAN, SCNX, TVRD, and BFRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIAN, SCNX, TVRD, and BFRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIAN, SCNX, TVRD, and BFRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LIAN, SCNX, TVRD, and BFRI Company Descriptions

Biofrontera NASDAQ:BFRI

LianBio NASDAQ:LIAN

Scienture NASDAQ:SCNX

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools